Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–7 of 7 stories
Roche has entered a partnership with SangeneBio potentially worth up to $1.7 billion to enhance its RNA interference (RNAi) portfolio. This deal complements Roche's existing RNAi initiatives, including the hypertension candidate zilbesiran, which is partnered with Alnylam.
Read full storyThe Million Hearts Initiative acknowledges two health systems for their effective strategies in managing high blood pressure among patients. This recognition highlights the importance of community efforts in chronic disease management.
The Million Hearts initiative launches the "Team Up. Pressure Down." program to enhance blood pressure control among Americans. This collaborative effort includes educational resources and tools for patients to manage their blood pressure effectively.
A new CDC report reveals that despite treatment, the majority of Americans with high blood pressure still struggle to control their condition. Millions remain untreated or unaware of their hypertension, highlighting a significant public health challenge.
The Community Preventive Services Task Force recommends team-based care for enhancing blood pressure control, citing strong evidence of its effectiveness. This recommendation could influence future healthcare policies and practices aimed at managing hypertension.
A CDC report reveals that two-thirds of U.S. adults with high cholesterol and half of those with high blood pressure are not receiving effective treatment, increasing their risk for heart attack and stroke. This highlights a critical gap in cardiovascular health management.
CDC will hold a media briefing to discuss new reports on the prevalence of high blood pressure and high cholesterol among U.S. adults. This event aims to raise awareness about these common health issues.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.